HSBC Holdings’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-253,660
| Closed | -$33.5M | – | 3294 |
|
|
2025
Q1 | $33.5M | Buy |
+253,660
| New | +$31.6M | 0.02% | 584 |
|
|
2024
Q3 | – | Sell |
-13,986
| Closed | -$958K | – | 3198 |
|
|
2024
Q2 | $958K | Sell |
13,986
-12,692
| -48% | -$880K | ﹤0.01% | 1704 |
|
|
2024
Q1 | $1.85M | Buy |
26,678
+21,692
| +435% | +$1.49M | ﹤0.01% | 1517 |
|
|
2023
Q4 | $357K | Buy |
4,986
+68
| +1% | +$3.91K | ﹤0.01% | 2205 |
|
|
2023
Q3 | $256K | Buy |
4,918
+1,259
| +34% | +$73.3K | ﹤0.01% | 2292 |
|
|
2023
Q2 | $232K | Buy |
+3,659
| New | +$228K | ﹤0.01% | 2261 |
|
|
2023
Q1 | – | Sell |
-3,954
| Closed | -$210K | – | 3118 |
|
|
2022
Q4 | $210K | Buy |
+3,954
| New | +$198K | ﹤0.01% | 2747 |
|
|
2021
Q1 | – | Sell |
-9,088
| Closed | -$290K | – | 3192 |
|
|
2020
Q4 | $290K | Buy |
+9,088
| New | +$239K | ﹤0.01% | 2589 |
|
|
2020
Q3 | – | Sell |
-11,940
| Closed | -$306K | – | 2893 |
|
|
2020
Q2 | $306K | Buy |
+11,940
| New | +$242K | ﹤0.01% | 2114 |
|
|
2019
Q4 | – | Sell |
-36,654
| Closed | -$274K | – | 3220 |
|
|
2019
Q3 | $274K | Buy |
+36,654
| New | +$351K | ﹤0.01% | 2686 |
|
|
2018
Q4 | – | Sell |
-48,357
| Closed | -$1.05M | – | 2750 |
|
|
2018
Q3 | $1.05M | Buy |
48,357
+36,791
| +318% | +$769K | ﹤0.01% | 1726 |
|
|
2018
Q2 | $204K | Sell |
11,566
-83,242
| -88% | -$1.69M | ﹤0.01% | 2440 |
|
|
2018
Q1 | $2M | Buy |
+94,808
| New | +$1.85M | ﹤0.01% | 1425 |
|
|
2017
Q1 | – | Sell |
-10,736
| Closed | -$162K | – | 2641 |
|
|
2016
Q4 | $162K | Buy |
+10,736
| New | +$152K | ﹤0.01% | 2571 |
|
Other funds holding ITCI
HSBC Holdings's ITCI Position: Q2 2025 in Review
HSBC Holdings sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 253,660 shares — an estimated $33.5M sold.
HSBC Holdings first reported a position in ITCI in Q4 2016 and held it in 14 quarters. The position peaked at $33.5M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- HSBC Holdings reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- HSBC Holdings sold 253,660 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $33.5M.
- HSBC Holdings first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 14 quarters.
- HSBC Holdings's Intra-Cellular Therapies Inc. position peaked at $33.5M in Q1 2025.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.